Floatz logo

13 assets in Acute Monocytic Leukemia

Therapeutic assets addressing Acute Monocytic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cytarabine
Acute Monocytic Leukemia
Chinese PLA General HospitalP3BBB (78)
Daunomycin
Acute Monocytic Leukemia
National Cancer Institute (NCI)P3BBB (77)
Mitoxantrone
Acute Monocytic Leukemia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP2/3BBB (74)
Nivestim
Acute Monocytic Leukemia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP3BBB (74)
Idarubicin
Acute Monocytic Leukemia
Chinese PLA General HospitalP3BBB (73)
Azacitidine
Acute Monocytic Leukemia
OHSU Knight Cancer InstituteP2BB (69)
Decitabine
Acute Monocytic Leukemia
Roswell Park Cancer InstituteP3BB (66)
Cladribine
Acute Monocytic Leukemia
OHSU Knight Cancer InstituteP2/3BB (64)
Gemtuzumab Ozogamicin
Acute Monocytic Leukemia
National Cancer Institute (NCI)P2BB (64)
Sorafenib
Acute Monocytic Leukemia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP2/3B (62)
Venetoclax
Acute Monocytic Leukemia
OHSU Knight Cancer InstituteP2B (60)
Tucidinostat
Acute Monocytic Leukemia
The First Affiliated Hospital of Soochow UniversityP2CCC (53)
Stx-0712
Acute Monocytic Leukemia
Solu Therapeutics, IncP1CC (43)